Comment on

• A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.

  Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G. Sargent DJ, et al. N Engl J Med. 2001 Oct 11;345(15):1091-7. doi: 10.1056/NEJMoa010957. N Engl J Med. 2001. PMID: 11596588
• Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer.

  Bass A. Bass A. J Clin Oncol. 2011 Jul 1;29(19):2728-9. doi: 10.1200/JCO.2011.36.1816. Epub 2011 Jun 6. J Clin Oncol. 2011. PMID: 21646605 No abstract available.
• Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.

  Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, Chua A, Shivasami A, Cummins MM, Murone C, Tebbutt NC. Price TJ, et al. J Clin Oncol. 2011 Jul 1;29(19):2675-82. doi: 10.1200/JCO.2010.34.5520. Epub 2011 Jun 6. J Clin Oncol. 2011. PMID: 21646616 Clinical Trial.